Spyre Therapeutics, Inc.SYRENASDAQ
Loading
Operating cash flow minus capital expenditures
Latest
$-169.25M
↓ 116% vs avg
Percentile
P0
Near historical low
Streak
4 yr
Consecutive declineContracting
Average
$-78.52M
Historical baseline
| Period | Value | YoY Change |
|---|---|---|
| TTM | $-169.25M | -7.5% |
| 2024 | $-157.41M | -57.6% |
| 2023 | $-99.91M | -24.6% |
| 2022 | $-80.18M | -47.7% |
| 2021 | $-54.29M | +32.2% |
| 2020 | $-80.06M | -19.2% |
| 2019 | $-67.18M | -106.0% |
| 2018 | $-32.62M | -29.3% |
| 2017 | $-25.23M | -32.4% |
| 2016 | $-19.05M | - |